AGAhmet Hakan Gedik

Ahmet Hakan Gedik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmet Hakan Gedik has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Total oxidant and antioxidant status and paraoxonase 1 levels of children with noncystic fibrosis bronchiectasis

    by Ahmet Hakan Gedik, Erkan Cakir, Aysel Vehapoglu Turkmen, Omer Faruk Ozer, Sare Betul Kaygusuz

    Background/aim: To evaluate total oxidant status (TOS), total antioxidant capacity (TAC), and paraoxonase 1 (PON1) levels in children with noncystic fibrosis (CF) bronchiectasis (BE), and to compare these levels with those of healthy controls. The study parameters were also evaluated according to some demographic, anthropometric, and clinical characteristics, as well as lung functions. Materials and methods: Enrolled in the study were 118 children with non-CF BE and 68 healthy controls. Serum TOS, TAC, and PON1 levels were determined. Lung function tests were performed by spirometry. Results: Serum TOS was higher in the patients [median 9.54 (IQR 25-75 = 7.05-13.30) mu mol H2O2 Eq/L] than in the healthy subjects [6.64 (5.45-9.53) mu mol H2O2 Eq/L] (P < 0.001). TAC was higher in patients with non-CF BE [1.07 (1.0-1.07) mmol Trolox Eq/L] than in the healthy controls [0.87 (0.77-0.98) mmol Trolox Eq/L] (P < 0.001). In addition, serum PON1 levels were significantly higher in the patients [106.5 (42.5-154.2) U/L] than in the controls [47.7 (27.5-82.1) U/L] (P < 0.001). The patients with low FEV1 had decreased TAC when compared to those who had normal FEV1 in non-CF BE. Conclusion: The present study demonstrated that compared with the control group the children with non-CF BE had elevated oxidative status, antioxidant defenses parameters, and PON1 values.


  • Flexible Fiberoptic Bronchoscopy Through the Laryngeal Mask Airway in a Small Premature Infant

    by Ahmet Hakan Gedik, Erkan Çakır, Ufuk Topuz

    Flexible bronchoscopy (FB) can be used safely for wider indications in children. Ultra-thin bronchoscopes are used for premature or newborn infants and are of limited diagnostic value. Bronchoscopes with a suction channel, may lead to problems when the nasal passage is narrow, particularly in patients under 2.5 kg. In addition, it may cause bronchospasm and hypoxia in small infants during the procedure because of an almost complete obstruction of the airway. A laryngeal mask airway (LMA) may prevent both bronchospasm and hypoxia because it does not need a nasal route. In addition, the LMA allows positive pressure ventilation during the procedure. We performed FB with a 3.7 mm bronchoscope through the LMA in a 75-day-old and 1910 g premature baby with atelectasis. This is the first and successful FB experience in such a small premature infant reported in the literature using a 3.7 mm bronchoscope through the LMA.


  • Open Access

    Evaluation of 563 children with chronic cough accompanied by a new clinical algorithm

    by Ahmet Hakan Gedik, Erkan Cakir, Emel Torun, Aysegul Dogan Demir, Mehmet Kucukkoc, Ufuk Erenberk, Selcuk Uzuner, Mustafa Nursoy, Emin Ozkaya, Fadlullah Aksoy, et al.

    This study aims to evaluate the children with chronic cough and to analyze their etiological factors according to the age groups. Five hundred sixty-three children with chronic cough were included. The last diagnosis were established and were also emphasized according to the age groups. The mean age was 5.4 ± 3.8 years (2-months–17-years) and 52 % of them were male. The most common final diagnosis from all the participants were: asthma (24.9 %), asthma-like symptoms (19 %), protracted bacterial bronchitis (PBB) (11.9 %), and upper airway cough syndrome (9.1 %). However, psychogenic cough was the second most common diagnosis in the subjects over 6 years of age. Asthma and asthma-like symptoms were the most common diagnosis in children. Different age groups in children may have a different order of frequencies. Psychogenic cough should be thought of in the common causes especially in older children.


  • Cathelicidin (LL‐37) and human β2‐defensin levels of children with post‐infectious bronchiolitis obliterans

    by Ahmet Hakan Gedik, Erkan Cakir, Yasemin Gokdemir, Zeynep Seda Uyan, Abdurrahim Kocyigit, Emel Torun, Bulent Karadag, Refika Ersu, Fazilet Karakoc

    Introduction: The antimicrobial peptides (AMPs) human β‐defensins and cathelicidin (LL‐37) are key factors in innate and adaptive immune responses of the respiratory tract and play an important role in many respiratory diseases. No data are available in the literature about the levels of these AMPs in paediatric patients with post‐infectious bronchiolitis obliterans (BO). This study aimed to determine human β‐defensin 2 (hBD2) and LL‐37 levels and compare between post‐infectious BO patients and the control group.Method: The patients diagnosed with post‐infectious BO between September 2012 and 2013 and age‐ and‐gender matched healthy controls were enrolled in this multi‐center study. Serum hBD2 and LL37 levels were determined with the enzyme‐linked immunosorbent assay method.Results: Sixty‐three post‐infectious BO patients and 65 healthy children (median age 73 ± 55 and 78.74 ± 36.32 months, respectively) were enrolled in the study. The mean of hBD2 levels in patients and the control group were 1.06 ± 0.24 and 0.67 ± 0.72 ng/mL, respectively (P < 0.001). The mean of LL‐37 levels in patients and the control group were 72.13 ± 29.06 and 50.10 ± 21.98 ng/mL, respectively (P < 0.001). No correlation was found between these AMPs levels and chronological age, age at the time of diagnosis, gender, Z‐scores of weight and length, hospitalization numbers, the disease history before diagnosis and 25‐OH D vitamin levels.Conclusion: This is the first study to demonstrate the higher levels of serum hBD2 and LL‐37 levels in paediatric post‐infectious BO patients. These AMPs may have important roles in the immune systems and pathogenesis of these patients.


  • Tuberculin skin test positivity without tuberculosis contact: A major challenge in childhood

    by Ahmet Hakan Gedik, Erkan Cakir, Tugrul Donmez, Engin Ari, Orhan Kaya Koksalan

    Worldwide, tuberculin skin tests (TSTs) commonly give false positive results for those who had been given the Bacillus-Calmette-Guerin vaccine such as is routinely administered in Turkey. This study aimed to evaluate the patients referred to us who had positive TSTs despite lack of tuberculosis (TB) disease contacts.Between September 2011 and September 2012, 183 patients were prospectively evaluated for differential diagnosis of TST positivity despite lack of TB disease contact. They were then followed up by us to determine an accurate diagnosis.Among our patients' most common symptoms indicating a need for TST were chronic cough, productive cough or sputum expectoration, and recurrent or persistent wheezing. Chest x-rays were taken of all patients, and the findings were noted. Interferon gamma release assays were performed on 75% of the patients, of which 96% were negative for TB. The most common final diagnoses were asthma (44%), allergic rhinitis (13%), bronchopneumonia (11%) and reactive lymphadenitis (6.5%). Further evaluations for TB were required of 36 patients, and TB disease was established in 12 of them (6.5%).In patients who had had no known TB contact, the most common symptom indicating need for TST was chronic cough; the most common diagnoses were asthma and allergic rhinitis. Cavitary lesions, haemoptysis, persistent infiltration, pleural effusion and thoracic lymphadenopathy despite antibiotherapy should alert physicians to the possibility of TB.


  • Open Access

    Can Appropriate Diagnosis and Treatment of Childhood Asthma Reduce Excessive Antibiotic Usage?

    by Ahmet Hakan Gedik, Erkan Cakir, Emin Ozkaya, Engin Ari, Mustafa Nursoy

    Introduction: This study compared the frequency of antibiotic usage and the number of asthma episodes before and after the diagnosis and treatment of pediatric asthma patients who were followed up by specialists. Subjects and Methods: Included in this study were 334 patients (211 males and 123 females) of 2-16 years of age who were diagnosed with asthma and followed up for at least 1 year in our clinic. The frequency of antibiotic usage and the number of asthma episodes in the year prior to diagnosis and treatment were compared to these same variables after 1 year of follow-up by specialists. Results: The median age was 84 months (range: 24-192) and 212 (63%) children were at school or in day care centers. Atopy and a family history of asthma were present in 200 (60%) of the patients, and 137 (41%) reported that at least one member of their household smoked. Antibiotics were used a median number of 7 times [interquartile range (IQR) = 6] in the year before the asthma diagnosis, and 2 times (IQR = 3) during the year after treatment (p < 0.001). The mean number of asthma episodes before diagnosis, i.e. 4 (IQR = 8) was reduced to 0 (IQR = 2) in the year after treatment when the patients were followed up by specialists (p < 0.001). Conclusion: This study shows that appropriate diagnosis and treatment of childhood asthma significantly reduce the frequency of antibiotic usage and the number of asthmatic episodes.


  • Therapeutic Plasma Exchange for Malignant Refractory Status Epilepticus: A Case Report

    by Ahmet H. Gedik, Demet Demirkol, Burak Tatlı, Suleyman Bayraktar, Alpay Alkan, Metin Karabocuoglu, Adnan Yuksel


  • Endobronchial lesion due to pulmonary Fusobacterium nucleatum infection in a child

    by Ahmet H. Gedik, Erkan Cakir, Omer Soysal, Tarık Umutoğlu

    Summary Clinically significant infections due to the members of the genus Fusobacterium are rare. The clinical manifestations of pulmonary Fusobacterium nucleatum infections range from simple aspiration pneumonia to severe diseases as necrotizing pneumonia, lung abscess, and empyema. Endobronchial lesions and obstructions are rarely seen in children and are often a misdiagnosed result in delay of definitive treatment. Here, we report a case of endobronchial lesion due to pulmonary F. nucleatum infection in an entirely healthy child before illness. This is the first case reported in the literature of endobronchial lesion due to pulmonary F. nucleatum infection. Pediatr Pulmonol. 2014; 49:E63–E65.


  • Open Access

    Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?

    by Demet Demirkol, Dincer Yildizdas, Benan Bayrakci, Bulent Karapinar, Tanil Kendirli, Tolga F Koroglu, Oguz Dursun, Nilgün Erkek, Hakan Gedik, Agop Citak, et al.

    Introduction: Hyperferritinemia is associated with increased mortality in pediatric sepsis, multiple organ dysfunction syndrome (MODS), and critical illness. The International Histiocyte Society has recommended that children with hyperferritinemia and secondary hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) should be treated with the same immunosuppressant/cytotoxic therapies used to treat primary HLH. We hypothesized that patients with hyperferritinemia associated secondary HLH/sepsis/MODS/MAS can be successfully treated with a less immunosuppressant approach than is recommended for primary HLH. Methods: We conducted a multi-center cohort study of children in Turkish Pediatric Intensive Care units with hyperferritinemia associated secondary HLH/sepsis/MODS/MAS treated with less immunosuppression (plasma exchange and intravenous immunoglobulin or methyl prednisolone) or with the primary HLH protocol (plasma exchange and dexamethasone or cyclosporine A and/or etoposide). The primary outcome assessed was hospital survival. Results: Twenty-three children with hyperferritinemia and secondary HLH/sepsis/MODS/MAS were enrolled (median ferritin = 6341 μg/dL, median number of organ failures = 5). Univariate and multivariate analyses demonstrated that use of plasma exchange and methyl prednisolone or intravenous immunoglobulin (n = 17, survival 100%) was associated with improved survival compared to plasma exchange and dexamethasone and/or cyclosporine and/or etoposide (n = 6, survival 50%) (P = 0.002). Conclusions: Children with hyperferritinemia and secondary HLH/sepsis/MODS/MAS can be successfully treated with plasma exchange, intravenous immunoglobulin, and methylprednisone. Randomized trials are required to evaluate if the HLH-94 protocol is helpful or harmful compared to this less immune suppressive and cytotoxic approach in this specific population.